Search
Selected Filter
Displaying 341–350 of 504 news results
-
Foundation Invests $2.5 Million in Search for Elusive Retinal Disease Genes and Mutations
Research NewsSince 1989 genetic researchers, many funded by the Foundation, have identified approximately 270 genes linked to IRDs. In most cases, defects in a single gene can cause a retinal disease and vision loss.
-
Recording Available for Achromatopsia Teleconference Hosted by AGTC, Foundation, and Achroma Corp
Research NewsApplied Genetic Technologies Corporation (AGTC), Achroma Corp, and the Foundation Fighting Blindness hosted a one-hour teleconference on the condition. The call highlighted the difficulties patients have in getting a diagnosis for achromatopsia, the importance of genetic testing, and gene therapy clinical trials underway.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Foundation NewsMore than two decades ago, the Foundation Fighting Blindness (FFB) began funding RPE65 gene therapy research that led in late 2017 to LUXTURNA™, the first FDA-approved gene therapy for the eye or an inherited condition. Ultimately, the Foundation provided more than $10 million in funding for the groundbreaking effort.
-
Apellis Launches Phase 3 Clinical Trial Program for Advanced Dry AMD Treatment
Research NewsTrial participants will receive intravitreal injections of APL-2, or a sham procedure (placebo), monthly or every other month. The injections are made into the vitreous, the soft gel in the middle of the eye.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Research NewsOn September 4, 2018, seven researchers, including six previously funded by the Foundation, were recognized with the prestigious 2018 Antonio Champalimaud Vision Award for their contributions to the advancement of blindness-reversing RPE65 gene therapies.
-
Vision Improvements Reported in ProQR's Clinical Trial for LCA10 Treatment
Research NewsThe company reported that 60 percent of subjects in the trial demonstrated improvements in visual acuity and their ability to navigate a mobility course. The treatment was also safe for patients.
-
Foundation News
The Foundation Fighting Blindness (FFB), the world’s leading private funding source for inherited retinal disease research, announced major awards in two areas: promising research projects in retinal diseases and career development for clinical researchers.
-
Ophthotech is Advancing an Impressive Portfolio of Cutting-Edge Therapies for Retinal Diseases
Research NewsThe company is taking on a multi-track strategy that includes retinal gene-therapy development, including delivery of over-sized genes and design of a two-step process of gene knockdown and replacement for autosomal dominant conditions.
-
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Research NewsEach recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
FFB Funding More than $2 Million in New Research
Research NewsSeventy scientists submitted requests for funding.
